ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus(MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa. Source
No articles found.
We are a global medical technology company that develops, manufactures, and market...
We are a global medical technology company that...
Aileron Therapeutics is a clinical stage company discovering and developing novel ...
Aileron Therapeutics is a clinical stage compan...
Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company ...
Innovate is a publicly traded (Nasdaq: INNT) cl...
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical com...
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a c...
We exist to create an alternate future for people living with neurodegenerative di...
We exist to create an alternate future for peop...
BiondVax is an innovative biopharmaceutical company developing a universal flu vac...
BiondVax is an innovative biopharmaceutical com...
SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focus...
SIGA Technologies, Inc. is a public, commercial...
Join the National Investor Network and get the latest information with your interests in mind.